These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12108335)

  • 1. [Nadir PSA and kinetics of PSA decline between the 3rd and 6th month after external beam radiotherapy for T1 T2 Nx M0 localized prostate cancer: value of the prediction of the risk of biological progression].
    Almeras C; Zerbib M; Eschwege F; Debré B
    Prog Urol; 2002 Apr; 12(2):219-25. PubMed ID: 12108335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D; Cellier P; Dalifard I; Pabot du Chatelard P; Chaussis F; Vielle B; Soret JY; Passagot J; Courte C; Daver A
    Prog Urol; 2002 Jun; 12(3):421-8. PubMed ID: 12189749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of PSA nadir and the time to nadir in the disease-free period in localized prostatic carcinoma treated with radical radiation].
    Cambeiro M; Azinovic I; Villafranca E; Moreno-Jiménez M; Cañón R; Aristu JJ; Beltrán C; López-Picazo JM; Fernández J; Rebollo J
    Rev Med Univ Navarra; 2001; 45(1):20-8. PubMed ID: 11488204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model.
    Cavanaugh SX; Kupelian PA; Fuller CD; Reddy C; Bradshaw P; Pollock BH; Fuss M
    Cancer; 2004 Jul; 101(1):96-105. PubMed ID: 15221994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure.
    Kamat AM; Rosser CJ; Levy LB; Chichakli R; Lee AK; Cheung MR; Pisters LL
    Urology; 2004 Jun; 63(6):1132-7. PubMed ID: 15183966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
    Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
    Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
    Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA bouncing after short term androgen deprivation and 3D-conformal radiotherapy for localized prostate adenocarcinoma and the relationship with the kinetics of testosterone.
    Akyol F; Ozyigit G; Selek U; Karabulut E
    Eur Urol; 2005 Jul; 48(1):40-5. PubMed ID: 15967250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
    Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postradiotherapy PSA nadirs fail to support dose escalation study in patients with pretreatment PSA values < 10 ng/ml.
    Herold D; Hanks G; Movsas B; Hanlon A
    Radiat Oncol Investig; 1997; 5(1):15-9. PubMed ID: 9303052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.